stockrow
Friday 6 November 2026
Export FBIO’s income statement to Excel — free account
Fortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −116.0%
- Free cash flow
- −115.4%
- Total debt
- −35.7%
Quarter to June 2026, against a year earlier
1.85
0.01
+0.54%
Follow FBIO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 5 | 7 | 6 |
| (20.35%) | (6.22%) | 101.51% | 84.91% | ||
| (3.46%) | (1.14%) | 44.56% | 43.38% | ||
ROIC |
(209.25%) | (124.61%) | 0.00% | (41.34%) | |
Return on Tangible Assets |
(7.96%) | (2.46%) | 61.28% | 55.60% | |
Average Days of Receivables |
106.18 | 172.75 | 140.72 | 195.93 | |
Free Cash Flow per Share |
(2.39) | (2.32) | 5.00 | 3.96 | |
Free Cash Flow |
(65.04) | (64.61) | 157.64 | 125.84 | |
Capital Expenditures |
1.10 | 1.17 | — | (0.08) | |
| Other line items | |||||
Cash ROIC |
(32.65%) | (33.31%) | 31.84% | 28.78% | |
Accounts Receivable Turnover |
4.30 | 3.14 | 3.02 | 2.59 | |
Accounts Payable Turnover |
0.37 | 0.37 | 0.28 | 0.48 | |
Inventory Turnover |
1.71 | 1.74 | 2.05 | 2.24 | |
Average Days of Payables |
817.71 | 822.05 | 1,518.43 | 764.29 | |
Days of Inventory on Hand |
213.93 | 167.88 | 151.74 | 126.38 | |
Tax Rate |
0.01 | (0.02) | (0.03) | (0.03) | |
Research and Development Expense of Revenue |
35.63% | 18.81% | 12.85% | 1.73% | |
Selling, General and Administrative Expense of Revenue |
174.64% | 152.38% | 130.94% | 100.31% | |
Share Based Compensation of Revenue |
68.17% | 45.43% | 37.53% | 15.03% | |
Interest Coverage |
(8.40) | (6.95) | (5.22) | (3.03) | |
Operating CF/Net income |
12.39 | 34.95 | 1.32 | 1.22 | |
Depreciation/Fixed assets |
3.04 | 3.18 | 3.79 | 3.67 | |
Capex/Depreciation |
0.14 | 0.15 | 0.00 | (0.01) | |
Revenue per Share |
2.29 | 2.27 | 2.10 | 2.15 | |
Operating CF per Share |
(2.43) | (2.36) | 5.00 | 3.96 | |
Capex per Share |
0.04 | 0.04 | 0.00 | 0.00 | |
Capex to Sales |
(0.02) | (0.02) | 0.00 | 0.00 |
Columns are period end dates